Literature DB >> 2891093

Possible presence of [3H]glutathione (GSH) binding sites in synaptic membranes from rat brain.

K Ogita1, Y Yoneda.   

Abstract

Reduced as well as oxidized forms of glutathione exhibited a significant displacement of the specific binding of [3H]L-glutamic acid (Glu), a potential candidate for the central excitatory neurotransmitter, to the rat brain synaptic membranes. In order to elucidate these findings, an attempt was made to determine whether or not the synaptic membranes contained the binding sites for this peptide using [3H]glutathione (GSH) as a ligand. The specific binding activity was detected in the synaptic membranous preparations and found to be dependent on the incubation temperature and incubation time. The binding reached a plateau within 60 min of incubation at 2 degrees C and 30 degrees C. [3H]GSH binding increased linearly with increasing concentrations of membranous proteins employed. Scatchard analysis revealed that the binding sites consisted of two separate independent components rather than being comprised of a single constituent. A significant and concentration-dependent displacement of the binding was induced not only by the addition of GSH, but also by the inclusion of some GSH derivatives without SH-moiety, such as the oxidized form of glutathione, S-methyl-glutathione and S-hexyl-glutathione. The binding was also significantly inhibited by various alpha- and gamma-peptides containing L-Glu, but not by those containing D-Glu. Amongst 4 different agonists and antagonists used for the subclassification of the central Glu receptors, an agonist, quisqualic acid, and an antagonist, 2-amino-4-phosphonobutyric acid, exhibited a significant inhibition of the binding at the highest concentration employed. These results suggest that the rat brain synaptic membranes may contain structure-selective, temperature-dependent, high affinity and saturable binding sites for glutathione.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2891093     DOI: 10.1016/0168-0102(87)90037-x

Source DB:  PubMed          Journal:  Neurosci Res        ISSN: 0168-0102            Impact factor:   3.304


  7 in total

1.  Glutathione is an endogenous ligand of rat brain N-methyl-D-aspartate (NMDA) and 2-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptors.

Authors:  V Varga; Z Jenei; R Janáky; P Saransaari; S S Oja
Journal:  Neurochem Res       Date:  1997-09       Impact factor: 3.996

2.  Gclc deficiency in mouse CNS causes mitochondrial damage and neurodegeneration.

Authors:  Weiyi Feng; Mariana Rosca; Yuxuan Fan; Yufen Hu; Pingfu Feng; Hyoung-Gon Lee; Vincent M Monnier; Xingjun Fan
Journal:  Hum Mol Genet       Date:  2017-04-01       Impact factor: 6.150

3.  Cardiovascular responses to l-glutamate microinjection into the NTS are abrogated by reduced glutathione.

Authors:  Álisson Silva Granato; Paula Magalhães Gomes; Renato William Martins Sá; Gabriel Silva Marques Borges; Andréia Carvalho Alzamora; Lisandra Brandino de Oliveira; Glenn M Toney; Leonardo M Cardoso
Journal:  Neurosci Lett       Date:  2017-02-09       Impact factor: 3.046

4.  Effects of exogenous factors on the cerebral glutathione in rodents.

Authors:  E Bien; K Vick; G Skorka
Journal:  Arch Toxicol       Date:  1992       Impact factor: 5.153

5.  Involvement of amino-acid side chains of membrane proteins in the binding of glutathione to pig cerebral cortical membranes.

Authors:  András Hermann; Vince Varga; Simo S Oja; Pirjo Saransaari; Réka Janáky
Journal:  Neurochem Res       Date:  2002-05       Impact factor: 3.996

6.  Targeting brain cells with glutathione-modulated nanoliposomes: in vitro and in vivo study.

Authors:  Heba F Salem; Sayed M Ahmed; Ashraf E Hassaballah; Mahmoud M Omar
Journal:  Drug Des Devel Ther       Date:  2015-07-20       Impact factor: 4.162

Review 7.  Glutathione in the Nervous System as a Potential Therapeutic Target to Control the Development and Progression of Amyotrophic Lateral Sclerosis.

Authors:  Kiyoung Kim
Journal:  Antioxidants (Basel)       Date:  2021-06-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.